Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Atrium Acquires DL Canada | Contract Pharma

What are you searching for?

Sign in
Breaking News

Atrium Acquires DL Canada

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Atrium Biotechnologies, Inc. has acquired the assets of London, Ontario-based Douglas Laboratories Canada (DL Canada). DL Canada has been marketing Douglas Laboratories products in Canada since 2000 and has current annual revenues of approximately $5 million. DL Canada’s current management and staff are staying on to ensure the successful integration of the two companies.

“This acquisition provides Atrium with a platform to develop the Canadian healthcare professional market not only for the Douglas Laboratories brand but also for the Pure Encapsulations brand which is not currently being sold in Canada. This acquisition further reinforces our current leadership position in North America and marks another step in our strategy to control access to markets and build solid organic growth for our brands,” said Richard Bordeleau, president of Atrium’s Health & Nutrition Division.

“Our company has been focused on growing the Douglas Laboratories’ business in Canada. We are convinced that under Atrium’s leadership we will accelerate our growth and we are very optimistic about the future especially with the synergies created by combining our companies,” stated Dr. Victoria Coleman-Kay, president of DL Canada.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters